- Home
- CISS vs MTNB Comparison
CISS vs MTNB Comparison
Compare CISS & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISS
- MTNB
- Stock Information
- Founded
- CISS 2022
- MTNB 2013
- Country
- CISS Greece
- MTNB United States
- Employees
- CISS N/A
- MTNB N/A
- Industry
- CISS Marine Transportation
- MTNB Biotechnology: Pharmaceutical Preparations
- Sector
- CISS Consumer Discretionary
- MTNB Health Care
- Exchange
- CISS Nasdaq
- MTNB Nasdaq
- Market Cap
- CISS 3.1M
- MTNB 3.1M
- IPO Year
- CISS N/A
- MTNB N/A
- Fundamental
- Price
- CISS $3.85
- MTNB $0.70
- Analyst Decision
- CISS
- MTNB Hold
- Analyst Count
- CISS 0
- MTNB 1
- Target Price
- CISS N/A
- MTNB N/A
- AVG Volume (30 Days)
- CISS 30.6K
- MTNB 39.2K
- Earning Date
- CISS 05-27-2025
- MTNB 05-20-2025
- Dividend Yield
- CISS N/A
- MTNB N/A
- EPS Growth
- CISS N/A
- MTNB N/A
- EPS
- CISS N/A
- MTNB N/A
- Revenue
- CISS $42,296,101.00
- MTNB N/A
- Revenue This Year
- CISS N/A
- MTNB N/A
- Revenue Next Year
- CISS N/A
- MTNB N/A
- P/E Ratio
- CISS N/A
- MTNB N/A
- Revenue Growth
- CISS 47.17
- MTNB N/A
- 52 Week Low
- CISS $2.85
- MTNB $0.48
- 52 Week High
- CISS $29.40
- MTNB $9.60
- Technical
- Relative Strength Index (RSI)
- CISS 48.93
- MTNB 62.94
- Support Level
- CISS $3.75
- MTNB $0.57
- Resistance Level
- CISS $4.10
- MTNB $0.65
- Average True Range (ATR)
- CISS 0.29
- MTNB 0.06
- MACD
- CISS 0.08
- MTNB 0.01
- Stochastic Oscillator
- CISS 67.78
- MTNB 79.03
About CISS C3is Inc.
C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of our fleet is approximately 64,000 dwt.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.